Lixi F, Giannaccare G, Salerno G, Gagliardi V, Pellegrino A, Vitiello L
J Pers Med. 2024; 14(12).
PMID: 39728071
PMC: 11678913.
DOI: 10.3390/jpm14121160.
Alamino V, Onofrio L, Acosta C, Ferrero P, Zacca E, Cadile I
Eur J Immunol. 2023; 53(8):e2250353.
PMID: 37179252
PMC: 10524217.
DOI: 10.1002/eji.202250353.
Harish Bindiganavile S, Bhat N, Lee A, Gombos D, Al-Zubidi N
J Immunother Precis Oncol. 2022; 4(1):6-15.
PMID: 35664825
PMC: 9161666.
DOI: 10.36401/JIPO-20-21.
Moore A, Burrows A, Malik R, Ghubash R, Last R, Remaj B
Vet Dermatol. 2022; 33(5):435-439.
PMID: 35644925
PMC: 9541829.
DOI: 10.1111/vde.13097.
Deya-Martinez A, Riviere J, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P
J Clin Immunol. 2022; 42(5):1071-1082.
PMID: 35486339
PMC: 9402491.
DOI: 10.1007/s10875-022-01257-x.
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
Palandri F, Breccia M, De Stefano V, Passamonti F
Cancers (Basel). 2021; 13(19).
PMID: 34638236
PMC: 8507529.
DOI: 10.3390/cancers13194750.
COVID-19-associated opportunistic infections: a snapshot on the current reports.
Abdoli A, Falahi S, Kenarkoohi A
Clin Exp Med. 2021; 22(3):327-346.
PMID: 34424451
PMC: 8381864.
DOI: 10.1007/s10238-021-00751-7.
Ruxolitinib Alleviates Uveitis Caused by Endotoxin.
Du L, Yip Y, Ng H, Ho B, He J, Chan S
Microorganisms. 2021; 9(7).
PMID: 34361917
PMC: 8307045.
DOI: 10.3390/microorganisms9071481.
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
March-Rodriguez A, Bellosillo B, Alvarez-Larran A, Besses C, Pujol R, Toll A
Ann Dermatol. 2021; 31(2):204-208.
PMID: 33911570
PMC: 7992689.
DOI: 10.5021/ad.2019.31.2.204.
Ocular Toxicity of Targeted Anticancer Agents.
Fortes B, Tailor P, Dalvin L
Drugs. 2021; 81(7):771-823.
PMID: 33788182
DOI: 10.1007/s40265-021-01507-z.
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.
Sadjadian P, Wille K, Griesshammer M
Cancers (Basel). 2020; 12(11).
PMID: 33114733
PMC: 7693745.
DOI: 10.3390/cancers12113132.
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y
Infect Drug Resist. 2020; 13:1017-1021.
PMID: 32308443
PMC: 7152536.
DOI: 10.2147/IDR.S249030.
A case report of cryptococcal meningitis associated with ruxolitinib.
Tsukui D, Fujita H, Suzuki K, Hirata K
Medicine (Baltimore). 2020; 99(13):e19587.
PMID: 32221077
PMC: 7220082.
DOI: 10.1097/MD.0000000000019587.
Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
Liisborg C, Hasselbalch H, Sorensen T
Cancers (Basel). 2020; 12(3).
PMID: 32121664
PMC: 7139696.
DOI: 10.3390/cancers12030573.
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.
Elli E, Barate C, Mendicino F, Palandri F, Palumbo G
Front Oncol. 2019; 9:1186.
PMID: 31788449
PMC: 6854013.
DOI: 10.3389/fonc.2019.01186.
Ruxolitinib for the Treatment of Essential Thrombocythemia.
Gunawan A, Harrington P, Garcia-Curto N, McLornan D, Radia D, Harrison C
Hemasphere. 2019; 2(4):e56.
PMID: 31723782
PMC: 6746005.
DOI: 10.1097/HS9.0000000000000056.
The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L, Bose P, Verstovsek S
Curr Hematol Malig Rep. 2019; 14(4):310-327.
PMID: 31228096
DOI: 10.1007/s11899-019-00527-7.
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
Prakash K, Richman D
BMC Infect Dis. 2019; 19(1):287.
PMID: 30917797
PMC: 6437885.
DOI: 10.1186/s12879-019-3922-6.
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
Maschmeyer G, De Greef J, Mellinghoff S, Nosari A, Thiebaut-Bertrand A, Bergeron A
Leukemia. 2019; 33(4):844-862.
PMID: 30700842
PMC: 6484704.
DOI: 10.1038/s41375-019-0388-x.
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
Krauth M, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Keil F
Wien Klin Wochenschr. 2018; 130(17-18):495-504.
PMID: 30043249
PMC: 6132876.
DOI: 10.1007/s00508-018-1365-5.
